dailypolitical.com
Positivewww.dailypolitical.com ·
analysts weekly ratings updates for esperion therapeutics espr
TAX_FNCACT_ANALYSTTAX_ECON_PRICECRISISLEX_C03_WELLBEING_HEALTHECON_ENTREPRENEURSHIP
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article reports analyst downgrades for Esperion Therapeutics, a biotech company developing cholesterol-lowering drugs. The downgrades reflect negative sentiment but no specific commercial mechanism (e.g., trial failure, regulatory setback, or revenue miss) is mentioned. The impact is company-specific and weak; no broader sector or supply chain effect is evident.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Multiple analysts downgraded Esperion Therapeutics (NASDAQ: ESPR) from buy/strong-buy to hold/neutral in early May 2026.
- HC Wainwright set a price target of $3.16 with a neutral rating.
- Weiss Ratings reaffirmed a sell (d-) rating on April 21, 2026.
- Esperion focuses on LDL-C lowering therapies for atherosclerotic cardiovascular disease.